NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, is scheduled to present at the 20th Annual H.C. Wainwright Global Investment Conference taking place on September 4-6, 2018 at The St. Regis New York.
Details of the presentation are below:
Event: 20th Annual H.C. Wainwright Global Investment Conference
Date: Thursday, September 6, 2018
Time: 4:15pm ET
Location: Fontainebleau Room (Floor 2)
A live webcast of the presentation may be accessed on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma and other eye diseases.
Company Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenoviabio.com
Investor Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: 646-536-7035/7037
E-mail: tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
kthomas@theruthgroup.com